Reduced-Risk Products Science Update
|
|
- Aron Jackson
- 5 years ago
- Views:
Transcription
1 Reduced-Risk Products Science Update Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science Forward-Looking Statements This presentation contains forward-looking statements. These statements appear in a number of places in this document and include statements regarding the intent, belief, or current and future expectations of our management with respect to our business, financial condition and results of operations. In some cases, you can identify forward-looking statements by terms such as may, will, should, would, expect, intend, project, plan, aim, seek, target, anticipate, believe, estimate, predict, potential or the negative of these terms or other similar terminology. These statements are not guarantees of future performance and are subject to various risks and uncertainties. Actual results, performance or achievements, or those of the industries in which we operate, may differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. In addition, these forward-looking statements are necessarily dependent upon assumptions, estimates and data that may be incorrect or imprecise and involve known and unknown risks and uncertainties. Forward-looking statements regarding operating results are particularly subject to a variety of assumptions, some or all of which may not be realized. Risks, uncertainties or other factors that could cause actual results to differ materially from those expressed in any forward-looking statement include, without limitation: (1) increase in awareness of health concerns related to smoking; (2) regulatory developments; including, without limitation, tax increases and restrictions on sales, marketing, packaging, labeling and use of tobacco products, privately imposed restrictions and governmental investigations; (3) litigation around the world alleging adverse health and financial effects resulting from, or relating to, tobacco products; (4) our ability to further diversify our business beyond the traditional tobacco industry; (5) our ability to successfully expand internationally and make investments outside Japan; (6) competition and changing consumer preferences; (7) our ability to manage impacts derived from business diversification or business expansion; (8) economic, regulatory and political changes, such as nationalization, terrorism, wars and civil unrest, in countries in which we operate; (9) fluctuations in foreign exchange rates and the costs of raw materials; and (10) catastrophes, including natural disasters. 2
2 This presentation contains images of our products in some slides. Those slides have been included exclusively to illustrate JT Group s strategy or performance to our investors. They are not to be used for any other purpose. 3 Science is central to our RRP business Multi-disciplinary expertise & international collaboration Fundamental Research Applied Science JTG R&D centers Austria, Germany, Japan, Poland, Sweden, Switzerland and the UK Reduced-Risk Assessment 4
3 Broadening spectrum of consumer needs Focus on Reduced-Risk potential Social Consideration $ Affordability Convenience Reduced Risk Potential Consumers are increasingly interested in experiences and products that address a broadening spectrum of personal and social needs Satisfaction 5 Combining risk-reduction potential & product acceptance To fulfill the Harm Reduction equation Risk-Reduction Product Potential X Harm Reduction Acceptance = $ 6
4 The JT Group approach to assessment of RRP The emission is our starting point 1 EMISSION What comes out of the product 2 UPTAKE Users exposure to emissions & uptake into the body 3 EFFECT Biological effects of uptake into the body 4 INDOOR AIR QUALITY Environmental impact simulations 7 Tobacco Infused Vapor How Ploom TECH works Tobacco Vapor Liquid Cartridge Tobacco Capsule Battery 8
5 1) 1 Emission The risk cliff concept Potential risk-reduction in T-Vapor products Cigarettes Temperature may be an indicator of risk HIGHER Charcoal Heated Heated Tobacco Tobacco Infused Vapor LOWER o C 9 1) 1 Emission Dramatically reduced levels of TPM in Ploom TECH Analysis of smoke & vapor constituents 3R4F Reference cigarette (control) Commercially available Heated Tobacco product E-cigarette Reduction in the nine constituents recommended by the WHO for reduction in cigarette smoke -99% 10 Reference: Internal JT Group Studies. Note: TPM stands for Total Particulate Matter.
6 2) 2 Uptake Clinical study design Biomarkers of exposure Existing adult smokers 60 adult smokers randomly selected 20 subjects used Ploom TECH Screened Randomized 20 subjects smoking abstinent 20 subjects continued to smoke The subjects used products ad libitum for 5 days 11 2) 2 Uptake Reductions similar to smoking abstinence Biomarkers of exposure Ploom TECH Use Smoking Abstinence 0% Exhaled CO NNK (NNAL) 1, 3 Butadiene (MHBMA) Acrolein (3-HPMA) Conventional cigarettes 20% 40% -85% -64% -89% -69% 60% 80% 100% Percentage Reduction 12 Reference: D. Yuki et al., Assessment of the exposure to harmful & potentially harmful constituents in healthy Japanese smokers using a novel tobacco vapor product vs. conventional cigarettes and smoking abstinence. Regul Toxicol Pharmacol. 96,
7 3) 3 Effect Less biological impact compared to smoking Analysis of cell viability [Cell Viability] 100% 90% 80% Reference cigarette Commercially available Heated Tobacco product E-cigarette A E-cigarette B Ploom TECH 70% 60% 50% 40% 30% 20% 10% 0% Puffs/L (logarithmic) ,000 10, , Reference: S. Munakata et al., Comparative effects of cigarette smoke and novel tobacco product vapor on in vitro cellular responses in human bronchial epithelial cells. Society of Toxicology 2017, Baltimore. 3) 3 Effect Less biological impact compared to smoking Analysis of oxidative stress (inflammation) [GSH-GSSG] 100% 90% 80% Reference cigarette Commercially available Heated Tobacco product E-cigarette A E-cigarette B Ploom TECH 70% 60% 50% 40% 30% 20% 10% 0% Puffs/L (logarithmic) ,000 10, , Reference: S. Munakata et al., Comparative effects of cigarette smoke and novel tobacco product vapor on in vitro cellular responses in human bronchial epithelial cells. Society of Toxicology 2017, Baltimore.
8 3) 3 Effect Observably less effect on tissue model, even at 10 times more puffs In vitro airway model Control (before exposure) 0 Puffs/L Smoking (3R4F cigarette) 200 Puffs/L 2,000 Puffs/L 15 Reference: Internal JT Group Studies. 4) 4 Indoor Air Quality Minimal impact Exhaled breath analysis [ug per exhalation] Ploom TECH Use No Product Use 0.0 Nicotine Formaldehyde Acetone Ammonia JT 16 Reference: H. Ichitsubo and M. Kotaki, Indoor air quality (IAQ) evaluation of a Novel Tobacco Vapor (NTV) product. Regul Toxicol Pharmacol. 92,
9 4) 4 Indoor Air Quality Minimal impact Simulation of an occupied smoking lounge [Units] Cigarette Use Ploom TECH Use No Product Use 1, Solanesol Nicotine 3-Ethenyl pyridine Formaldehyde Acetaldehyde Acetone Toluene TVOC PG Glycerol CO (ppm) Ammonia SPM (mg/m3) JT 17 Reference: H. Ichitsubo and M. Kotaki, Indoor air quality (IAQ) evaluation of a Novel Tobacco Vapor (NTV) product. Regul Toxicol Pharmacol. 92, Positive scientific results to date Summary of Reduced-Risk potential 1 EMISSION Our scientific assessments on 2 UPTAKE Ploom TECH are providing very encouraging results, 3 EFFECT highlighting its strong Reduced-Risk potential 4 INDOOR AIR QUALITY 18
10 Committed to scientific communication Follow our progress at JT-Science.com 19
Assessing the impact of Ploom TECH use on indoor air quality (IAQ)
Assessing the impact of Ploom TECH use on indoor air quality (IAQ) ISoNTech June 14, 2018 Dr. Ian Jones VP Reduced-Risk Products Science, JTI Reduce- Risk Products RRP Science Source reference for the
More informationJT Group Consolidated Financial Results 2018 First Quarter Results
JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Dr Catherine Goujon Ginglinger - Philip Morris International Research & Development,
More informationA study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design. Nathan Gale 1, Mike McEwan 1, Alison Eldridge 1, Neil
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Maya Mitova, Catherine Goujon Ginglinger, Michel Rotach, Serge Maeder Philip
More informationCardiovascular effects of nicotine vs. cigarette smoke
Cardiovascular effects of nicotine vs. cigarette smoke Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece National School of Public Health, Athens-Greece
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationHeated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences
Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences Global Forum on Nicotine 2017 Moira Gilchrist PhD Philip Morris International June 16th 2017 Important Information Reduced-Risk
More informationJTI Switzerland. JTI Schweiz 3
JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton
More informationThe importance of offering adult smokers a portfolio of potentially less harmful products
The importance of offering adult smokers a portfolio of potentially less harmful products International Symposium on Nicotine Technology June 15 th 2017 Thomas Mc Grath, PhD PMI R&D, Philip Morris Products
More informationE-Cigarettes: Current Perspective
E-Cigarettes: Current Perspective Aruni Bhatnagar, Ph.D. Professor of Medicine University of Louisville Louisville, KY Electronic Cigarettes E-cigarettes are electronic nicotine delivery systems (ENDS),
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More informationEvaluation of the Potential for Second-hand Exposure to E-cigarette Aerosol in an Office Environment
Evaluation of the Potential for Second-hand Exposure to E-cigarette Aerosol in an Office Environment Edward A. Robinson, Robert D. Leverette, and Manoj Misra Lorillard Tobacco Company 68 th TSRC Charlottesville,
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationOctober 2, 2018 Japan Tobacco Inc. The Effects of T-Vapor products on Indoor Air Quality
October 2, 2018 Japan Tobacco Inc. The Effects of products on Indoor Air Quality Study on the Impact of products on Indoor Air Quality Study Conductor Test tobacco product Japan Tobacco Inc. product A
More informationWhat is combustion and why is the absence of combustion important for heat not burn products
What is combustion and why is the absence of combustion important for heat not burn products Global Forum on Nicotine 2017 June 16 th 2017 Thomas Mc Grath PhD PMI R&D, Philip Morris Products S.A., Quai
More informationVAPING: What you need to know
VAPING: What you need to know Stephen Rohan - High School Principal Dan Szolek - Middle School Principal Corporal Brian Hartman- Beaver Township Police Amie Widrig - Public Health Nurse Mahoning County
More informationScientific Evidence for Evaluating Modified Risk Tobacco Products
Scientific Evidence for Evaluating Modified Risk Tobacco Products Presented to the IOM Committee on Scientific Standards for Modified Risk Tobacco Products May 9 th 2011, Washington DC 1 l Altria Client
More informationThe concept that not all tobacco and nicotine products
A Model Risk Continuum for Tobacco and Nicotine Products by Chris Proctor, Sudhanshu Patwardhan, and James Murphy The concept that not all tobacco and nicotine products present the same risks to human
More informationA proposed bridging approach for the assessment of novel tobacco products
A proposed bridging approach for the assessment of novel tobacco products Dr. Ian M. Fearon British American Tobacco (Investments) Limited R&D Centre Southampton, U.K. Agenda Insight into BAT R&D Evolution
More informationThe Changing Landscape of Tobacco: E-Cigarettes, E-Hookahs and More
38th Annual Family Medicine Intensive Review Course The Changing Landscape of Tobacco: E-Cigarettes, E-Hookahs and More Debbie Rushing, LADAC, CTTS-M Associate Branch Chief Tobacco Prevention and Cessation
More informationIndustry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November
Industry Post-Regulation E-Cigarette Summit 217 Tim Phillips, ECigIntelligence 17 th November 217 www.ecigintelligence.com Agenda 1 2 3 Post-TPD: Has regulation been a success? Heated Tobacco: a success?
More informationAssessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data
Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data Global Forum on Nicotine 2015 Bruce D. Clark PhD Philip Morris International
More informationIntroduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationRISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS
RISK FROM E-VAPOUR PRODUCTS FOR USERS AND BYSTANDERS Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece COI Past 36 months 1 study funded by non-profit
More informationGlobal E-Cigarette Market- Industry Analysis & Outlook ( )
Global E-Cigarette Market- Industry Analysis & Outlook (2016-2020) ----------------------------------------- Executive Summary Electronic cigarettes, also known as E-cigarettes, electronic nicotine delivery
More informationBiomarker of Exposure Reductions Upon Switching for 5 Days from Cigarettes to a Carbon Heated Tobacco Product (CHTP 1.0)
Biomarker of Exposure Reductions Upon Switching for Days from to a Carbon Heated Tobacco Product () A. Donelli, C. Tran, C. Haziza, J. Ancerewicz, G. de La Bourdonnaye, R. Weitkunat, and F. Lüdicke 8 healthy
More informationTobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment
Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment Global Forum on Nicotine 2016 Moira Gilchrist PhD Philip Morris International R&D June 17th
More informationModelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery
Global Nicotine Forum 2018 Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery Ed Stephens University of St Andrews Declaration: No conflicts of interest
More informationDiscussion points on Bill S-5
Disclaimer: The following document was developed to provide a brief set of discussion points for individuals wishing to discuss Bill S-5 with policy makers, politicians, senators or their advisers. It
More informationDuPont Nutrition & Health Craig Binetti, President
Craig Binetti, President Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this
More informationHeat-not-Burn Products: Scientific Assessment of Risk Reduction
Heat-not-Burn Products: Scientific Assessment of Risk Reduction Tobacco Merchants Association 2015 Annual Meeting Moira Gilchrist PhD Philip Morris International R&D May 20th 2015 The Objective is Harm
More informationE-Cigarettes: A Game Changer. Dr. Blake Brown Hugh C. Kiger Professor Agriculture and Resource Economics College of Agriculture & Life Sciences
E-Cigarettes: A Game Changer Dr. Blake Brown Hugh C. Kiger Professor Agriculture and Resource Economics College of Agriculture & Life Sciences What is an e-cigarette? Battery Cartridge Indicator Light
More informationJT Applies to Amend Retail Prices of Tobacco Products in Japan in Response to a Planned Excise Increase
FOR IMMEDIATE RELEASE Tokyo, August 14, 2018 JT Applies to Amend Retail Prices of Tobacco Products in Japan in Response to a Planned Excise Increase Japan Tobacco Inc. (JT) (TSE: 2914) today announces
More informationAerosol Characterisation of e-cigarettes. Ross Cabot, Anna Koc, Caner U. Yurteri & John McAughey
Aerosol Characterisation of e-cigarettes Ross Cabot, Anna Koc, Caner U. Yurteri & John McAughey European Aerosol Conference, Prague 2-6 September 2013 1 Organisation Background Description History Regulation
More informationRE: Docket No. FDA-2014-N , Electronic Cigarettes and the Public Health
VIA ELECTRONIC SUBMISSION June 30, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 RE: Docket No. FDA-2014-N-1936-0001, Electronic
More informationWHO work on smokeless tobacco. Dr Vinayak Prasad, WHO HQ Ms Sarah Emami, WHO HQ
WHO work on smokeless tobacco Dr Vinayak Prasad, WHO HQ Ms Sarah Emami, WHO HQ WHO provides technical assistance to Member States on SLT policies and programs: MPOWER package ( key demand reduction measures
More informationHarmful and potentially harmful constituents in e-cigarettes
Harmful and potentially harmful constituents in e-cigarettes Prof. Riccardo Polosa Institute of Internal Medicine Centre for the Prevention and Cure of Tabagism University of Catania - ITALY Global Forum
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationElectronic Cigarettes and the Medical Society
Electronic Cigarettes and the Medical Society Michele Coleman MPH, MPA 2014 WI Medical Society Health Policy Intern LRB 1844 Exempting electronic smoking devices from the types of smoking devices that
More informationE-Vapour (EVAP) Sub-Group 2017 Report. Kitzbühel, Austria October 10, 2017
E-Vapour (EVAP) Sub-Group 2017 Report Kitzbühel, Austria October 10, 2017 History Evolution o 2014, formation of E-cigarette TF o 2016, TF activities completed; formation of E-vapor product SG 2 E-Vapour
More informationThe Global Network Aiming to deliver safe quality care in relation to tobacco for every service user, every time and everywhere
The Global Network Aiming to deliver safe quality care in relation to tobacco for every service user, every time and everywhere STRATEGIC PLAN 2015 2018 Use of Terms For the purpose of Global Network the
More informationAnalysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan
Analysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan A van der Plas, L Prieto, D Skiada, M Dobrynina, G Baker, F Ludicke PMI R&D, Philip Morris
More informationHealth (Tobacco, Nicotine etc. and Care)(Scotland) Bill. Japan Tobacco International (JTI)
Health (Tobacco, Nicotine etc. and Care)(Scotland) Bill Organisation name Japan Tobacco International (JTI) Japan Tobacco International (JTI) is part of the Japan Tobacco group (JT Group) of companies,
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCarl D. D Ruiz 1*, Donald W. Graff 2 and Edward Robinson 3
D Ruiz et al. BMC Public Health (2016) 16:543 DOI 10.1186/s12889-016-3236-1 RESEARCH ARTICLE Open Access Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and
More informationThe electronic cigarette (personal nicotine vaporizer)
The electronic cigarette (personal nicotine vaporizer) Murray Laugesen Health New Zealand Ltd nicotine and tobacco product researchers www.healthnz.co.nz Christchurch, New Zealand (c) www.healthnz.co.nz
More informationMight Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re
Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re 2 Agenda Smoking is still a problem Stopping is hard Electronic cigarettes Reduced Risk tobacco products Males >15yr
More informationDetermination of Emission Factors for Cigarettes and Electronic Cigarettes
Determination of Emission Factors for Cigarettes and Electronic Cigarettes Paul R. Nelson, John W. Caraway, Tao Jin, and Eckhardt Schmidt 69 th Tobacco Science Research Conference 21-September-2015 1 What
More informationBuilding Capacity for Tobacco Dependence Treatment in Japan. Request for Proposals (RFP) - Background and Rationale
Building Capacity for Tobacco Dependence Treatment in Japan Request for Proposals (RFP) - Background and Rationale Geographic Scope Japan Application process This application process has two steps: Letters
More informationStop the Vape. Maria Hines RN, MSN. Denise Kneubuhler RN, MSN
Stop the Vape Maria Hines RN, MSN Denise Kneubuhler RN, MSN https://78.media.tumblr.com/3a5eee652f16d0327cf3f4d8 8a63706c/tumblr_nzpw68ossS1rc7zl1o1_500.gif Objectives Increase awareness and knowledge
More informationE-cigarettes vs. Conventional Cigarettes and their Health Effects on the Environment. Elizabeth Do 5/01/15 GCH 360
E-cigarettes vs. Conventional Cigarettes and their Health Effects on the Environment Elizabeth Do 5/01/15 GCH 360 Introduction The rate of smoking has been declining in the United States, but the new discovery
More informationAssessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments
Assessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments C. Chrea, E. Spies, E. Afolalu, N. Mainy, S. Gallot, P. Binggeli, E. Clerc, R. Weitkunat PMI
More informationChallenges ahead to reach the goal set up in Tobacco End Game 2025
Challenges ahead to reach the goal set up in Tobacco End Game 2025 Dr Vera Luiza da Costa e Silva Head of the Convention Secretariat WHO FCTC 12 June 2018 Towards the end game 1. Where are we? 2. What
More informationThe Cigarette Market in Netherlands
The Cigarette Market in Netherlands Product Code: CG0148MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Austria report is a qualitative report providing extensive
More informationEXECUTIVE SUMMARY. 1 P age
EXECUTIVE SUMMARY The Global Adult Tobacco Survey (GATS) is the global standard for systematically monitoring adult tobacco use (smoking and smokeless) and tracking key tobacco control indicators. GATS
More informationREGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD
REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING Ron Borland PhD Tobacco Smoking Extremely harmful to health Kills over half of long-term users Reduces quality life years in most Slows recovery
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationCHARACTERIZING PASSIVE EXPOSURE TO TOBACCO SMOKE
this Paper, the health effects literature is described and evaluated using conventional standards of evidence accepted by the scientific community, and in relation to any specific standards that have been
More informationTOWNSHIP OF BRUCE MACOMB COUNTY, MICHIGAN ORDINANCE NO. 193 MINOR IN POSSESSION OF TOBACCO AND VAPOR PRODUCTS ORDINANCE TITLE.
TOWNSHIP OF BRUCE MACOMB COUNTY, MICHIGAN ORDINANCE NO. 193 MINOR IN POSSESSION OF TOBACCO AND VAPOR PRODUCTS ORDINANCE TITLE An Ordinance establishing restrictions on the possession of tobacco by minors
More informationThe Effect of Puff Profile and Volume on the Yields of E-Cigarettes
The Effect of Puff Profile and Volume on the Yields of E-Cigarettes Dr M J Taylor, Filtrona Technology Centre Smoke Science/Product Technology Meeting Seville, Spain, 29 September to 03 October 2013 Introduction
More informationGlobal Adult Tobacco Survey TURKEY. Dr. Peyman ALTAN MoH Tobacco Control Dep. Ankara November 2018
Global Adult Tobacco Survey TURKEY Dr. Peyman ALTAN MoH Tobacco Control Dep. Ankara November 2018 GATS Objectives GATS was launched as part of the Global Tobacco Surveillance System (GTSS) and it was first
More informationThe alcohol market is in need of a thorough review
Summary Alcohol, tobacco and gambling create costs for Swedish society in the form of production losses and extra expenditure for the public sector, for example. At the same time, these goods are valuable
More informationUniversity Policy TOBACCO-FREE POLICY
University Policy 800.02 TOBACCO-FREE POLICY Responsible Administrator: Vice President for Student Development and Services Responsible Office: Office of Student Development and Services Originally Issued:
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationREPORT ON THE 9TH JOINT CROSS-BORDER EMC MARKET SURVEILLANCE CAMPAIGN (2017) E-cigarettes. Final
REPORT ON THE 9TH JOINT CROSS-BORDER EMC MARKET SURVEILLANCE CAMPAIGN (2017) E-cigarettes Final Contents A. Executive summary... 3 B. Elements of the Campaign... 4 1. Introduction... 4 2. Reasons for the
More informationEisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai s In-house Discovered Anticancer Agent LENVIMA Eisai Conference for Media and
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationE-Cigarette Update: Secondhand Vapour
E-Cigarette Update: Secondhand Vapour Toxicity and Health Effects The popularity of e-cigarettes continues to increase, with more Canadians than ever using them indoors and out. The scientific evidence
More informationWHO Framework Convention on Tobacco Control
WHO Framework Convention on Tobacco Control When WHO was established in 1948, its Member States incorporated the power to negotiate treaties into its Constitution. This power remained dormant until 1996,
More informationTHE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE
THE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE Dr M J Taylor Director of Scientific Development Essentra Scientific Services CORESTA Congress Quebec 12 to 16 October
More informationE-Cigs, Etc.: Policy Options for Regulating Nicotine Delivery Devices. Indiana Local Boards of Health Webinar Feb. 12, 2015
E-Cigs, Etc.: Policy Options for Regulating Nicotine Delivery Devices Indiana Local Boards of Health Webinar Feb. 12, 2015 How to Use Webex If you can hear us through your computer, you do not need to
More informationCORESTA In vitro Toxicology Task Force. In vitro exposure of cells to Smoke at the Air Liquid Interface
CORESTA In vitro Toxicology Task Force In vitro exposure of cells to Smoke at the Air Liquid Interface Following the initial objective of the taskforce: To prepare a report to cover the rationale and strategy
More informationSmoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017
Smoking, e-cigs and reduced risk products Dr John Schoonbee, IMS November 2017 2 The storyline smoking is bad yet many folks still smoke because quitting is very hard is it better, if one cannot quit,
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationInvestor Day Reduced-Risk Products Lausanne, September 29, 2016
Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products Mirek Zielinski President, Reduced-Risk Products Investor Day Reduced-Risk
More informationElectronic Cigarettes, Nicotine and Policy Implications
Electronic Cigarettes, Nicotine and Policy Implications Neal L Benowitz MD University of California San Francisco The E-Cigarette Summit The Royal Society London November 17, 2016 Disclosures Dr Benowitz
More informationMeasure #404: Anesthesiology Smoking Abstinence National Quality Strategy Domain: Effective Clinical Care
Measure #404: Anesthesiology Smoking Abstinence National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate Outcome DESCRIPTION:
More informationE-Cigarette Product Regulation and Standardisation
E-Cigarette Product Regulation and Standardisation Derek Mariner British American Tobacco, Research & Development, Southampton UK E-cigarette Workshop, Paper STW03 CORESTA Smoke Science and Product Technology
More informationClearing The Air about: Gretchen Hagenbuch, M.Ed. SAP Coordinator Philadelphia Region
Clearing The Air about: Gretchen Hagenbuch, M.Ed. SAP Coordinator Philadelphia Region Caron Quick Facts Nationally recognized behavioral healthcare and addiction treatment facility Addiction treatment
More informationDavid S. Goya, DO, MBA, FCCP, FACP Kaiser Permanente Medical center Santa Clara, California
* * David S. Goya, DO, MBA, FCCP, FACP Kaiser Permanente Medical center Santa Clara, California None Electric Cigarette was patented in 1965 by Herbert Gilbert First introduced into the marketplace in
More informationNext Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21
Next Generation Products Sandra Costigan, Marianna Gaca, ChuanLiu, Kevin McAdam, James J. Murphyand Christopher Proctor British American Tobacco 21 st October 2015 Contents Evolution of products across
More informationThe Economics of Smoking
The Economics of Smoking One of the potential problems (from an economic perspective) with smoking is that there may be an externality in consumption, so there may be difference between the private and
More informationDECISION. Recalling further its decision FCTC/COP5(6) to adopt further partial guidelines;
66 Conference of the Parties to the WHO Framework Convention on Tobacco Control Seventh session Delhi, India, 7 12 November 2016 12 November 2016 DECISION FCTC/COP7(14) Further development of the partial
More informationExperimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes
Global Forum on Nicotine Rethinking Nicotine 2018 Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes Effects on acute craving, withdrawal, positive
More informationSurvey to Measure the Effectiveness of Electronic Cigarettes - October 2012
Survey to Measure the Effectiveness of Electronic Cigarettes - October 2012 Survey concludes that e-cigarette users feel better, have the support of friends and family, and save money compared to buying
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationElectronic Nicotine Delivery Systems
Electronic Nicotine Delivery Systems Michael Burke, EdD 2013 MFMER slide- # Learning objectives At the end of the presentation the participants should be able to Describe the history and patterns of use
More informationRegulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.
Regulatory Support for Tobacco Products Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help. PREMARKET TOBACCO (PMTA) HUMAN FACTORS STUDIES SUBSTANTIAL EQUIVALENCE
More informationGATS Highlights. GATS Objectives. GATS Methodology
GATS Objectives GATS Highlights The Global Adult Tobacco Survey (GATS) is a global standard for systematically monitoring adult tobacco use (smoking and smokeless) and tracking key tobacco control indicators.
More informationThe Benefits and Regulations of Electronic Cigarettes
Best Integrated Writing Volume 3 2016 The Benefits and Regulations of Electronic Cigarettes Sarah Kenney Wright State University Follow this and additional works at: http://corescholar.libraries.wright.edu/biw
More informationMARKETING STANDARDS FOR MEMBERSHIP
MARKETING STANDARDS FOR MEMBERSHIP The Vapor Technology Association (VTA) is a leading national trade association in the electronic cigarette and vapor product industry. VTA represents the manufacturers,
More informationGlobal impact of FDA-inspired tobacco regulatory science on jobs for chemists
Global impact of FDA-inspired tobacco regulatory science on jobs for chemists Sarah Cooney and Chris Proctor Group Research & Development, British American Tobacco, UK American Chemical Society Fall Meeting,
More information